Главная Обратная связь

Дисциплины:






Рекомендации к действию. Правительствам следует:



Правительствам следует:

1. запретить все ЭП препараты с высокой активностью, немедленно;

2. обеспечить наличие альтернативных форм тестирования на беременность и пропагандировать их использование;

3. широко освещать те опасности, которыми грозит использование любых лекарств во время беременности;

4. обеспечить доступ к простым, легальным, недорогим абортам, чтобы ликвидировать спрос на аборты путем самостоятельного применения в этих целях опасных продуктов.

 

 

Источники

1. Anon., "The untold story", Herald (Pakistan), Sept 1982.

2. Marcelis, С. and Shiva, M.,"EP drugs: unsafe by any name", in: McDonnell, K. (ed.), Adverse Effects: Women and the Pharmaceutical Industry, Penang, IOCU, 1986, pp11-26.

3. Salam, D.V., et al, "Estrogen-progesterone withdrawal bleeding in diagnosis of early pregnancy", International Journal of Gynaecology and Obstetrics, Vol 14, 1976, pp348-53.

4. Gal, I., et al, "Hormonal pregnancy tests and congenital malformations", Nature, Vol 216, 1967, p83.

5. See, for example: Levy, E.P., Cohen, A. and Eraser, F.C., "Hormone treatment during pregnancy and congenital heart defects", Lancet, 1973 (I), p611;
Janench, D.T.,Piper,J.M. and Glebatis, D.M., "Oral contraceptives and congenital limb-reduction defects", New England Journal of Medicine, Vol 291, 1974, pp697-700;
Nora, A.H. and Nora, J.J., "A syndrome of multiple congenital anomalies associated with teratogenic exposure", Archives of Environmental Health, Vol 30, 1975, pp17-21;
Hellstrom, В., Lindsten, J. and Nilsson, K., "Prenatal sex hormone exposure and congenital limb-reduction defects", Lancet, 1976 (II), p373;
Heinonen, O.P., Slone, D., et al, "Cardiovascular birth defects and antenatal exposure to female sex hormones", New England Journal of Medicine, Vol 296, 1977, pp67-70;
Janerich, J.T., Dugan, J.M., et al, "Congenital heart disease and prenatal exposure to exogenous sex hormones", British Medical Journal, 1977, pp1058-60;
Nora, J.J., Nora, A.H., et al, "Exogenous progestogen and estrogen implicated in birth defects", Journal of the American Medical Association, Vol 240, 1978, pp837-43.

6. United Nations, Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, 2nd issue, Doc No ST/ESA/192, New York,1987,pp111-12;
Marcelis and Shiva, op cit, pp11-26;
Gal, I., Teratological Adverse Drug Effects: Review of Evidence Implicating Hormonal Pregnancy Tests,(mimeo) submitted to UK Department of Health and Social Services, 1978/9, p3.



7. United Nations, op cit, pp112.

8. Silverman, M., Lydecker, M. and Lee, P.R., Bad Medicine: the prescription drug industry in the Third World, Stanford, Stanford University Press, 1992, p112.

9. AMA, Drug Evaluations, Philadelphia, W.B., Saunders Co.,(6th edn) 1986, p700.

10. WHO, The Effect of Female Sex Hormones on fetal Development and Infant Health, Technical Report Series, No 657, Geneva, 1981.

11. Marcelis and Shiva, op cit, pp11-26.

12. Voluntary Health Association of India (VHAI), The Case Against EP Forte, New Delhi, 1983, p1.

13. Wolffers, I., Hardon, A. and Janssen, J., Marketing Fertility: Women, Menstruation and the Pharmaceutical Industry, Amsterdam, WEMOS International Group on Women and Pharmaceuticals, 1989, p28.

14. Melrose, D., Report on Research and Networking Visit to Latin America, The Hague, HAI, 1983,
pp9-10.

15. Palaniappan, B. and Poorva Devi, V., "Hormones for withdrawal bleeding", Journal of the Indian Medical Association, Vol 74, No 4, 18 Feb 1980, p69.

16. WHO, op cit.

17. Silverman, et al, op cit, p117.

18. Phillips, A., Rakusen, J. (eds) and the Boston Women's Health Collective, The Neva Our Bodies, Ourselves (2nd UK edition), London, Penguin Books, 1989, p510.

19. Wolffers, et al, op cit, p25.

20. Anon., Herald, op cit.

21. Wolffers, et al, op cit, pp45-50.

22. Ibid, pp32 and 44.

23. MIMS Middle East, Vol 21, No 6, Dec 1990, pp81-2.

24. Qureshi,A.H. (ed.), Quick Index of Medical Preparations, Vol 22,No 1 and 2, Mar-Aug 1990, pp71-2.

25. MaLAM, Newsletter, Sep 1988, p1.

26. Silverman, et al, op cit, p118.

 


ЭНДРЮ ЧЕТЛИ. ПРОБЛЕМНЫЕ ЛЕКАРСТВА ЭНДРЮ ЧЕТЛИ. ПРОБЛЕМНЫЕ ЛЕКАРСТВА

Содержание :: ANTIBIOTIC.ru





sdamzavas.net - 2018 год. Все права принадлежат их авторам! В случае нарушение авторского права, обращайтесь по форме обратной связи...